Silencing JAK1 reduced JAK1 and JAK2 expression.<h4>Conclusion</h4>Baricitinib targets the JAK/STAT signaling pathway in macrophages, thereby exerting dual anti-inflammatory and anti-fibrotic inhibitory effects on CIA-ILD mice. Here, JAK1 is linked to interstitial lung disease.